Our patented Sound Bites platform offers a convenient, unbiased way for oncologists to stay up-to-date.

Critical, on-demand information right at your fingertips when and where it is most convenient for you. Subscribe to receive 60 – 90 second video clips from thought leaders via text message.

Free to healthcare providers. No ads, no sponsorships, no bias.

Intended for USA healthcare providers only.

Browse Clinical Trial Updates

All
ASCO Updates
Breast Cancer
GI Cancers
GU Cancers
GYN Oncology
Hematological Malignancies
Lung Cancer
Skin Cancer
Dr. Charu Aggarwal presents intracranial activity for datopotamab deruxtecan in pretreated mNSCLC (Video 3/3)

Dr. Charu Aggarwal presents intracranial activity for datopotamab deruxtecan in pretreated mNSCLC (Video 3/3)

TROPION Lung Intracranial

Charu Aggarwal, MD
Lung Cancer
Dr. Charu Aggarwal reviews safety highlights for datopotamab deruxtecan in pretreated mNSCLC (Video 2/3)

Dr. Charu Aggarwal reviews safety highlights for datopotamab deruxtecan in pretreated mNSCLC (Video 2/3)

TROPION Lung Safety

Charu Aggarwal, MD
Lung Cancer
Dr. Eric Singhi shows that PD-L1 expression is a spectrum in patients with aNSCLC (Video 2/3)

Dr. Eric Singhi shows that PD-L1 expression is a spectrum in patients with aNSCLC (Video 2/3)

EMPOWER PD-L1

Eric Singhi , MD
Lung Cancer
Dr. Gregory Vidal discusses the safety, tolerability, and patient management techniques for inavolisib + palbociclib + fulvestrant in 1L PIK3CAm HR+, HER2- ABC (Video 2/2)

Dr. Gregory Vidal discusses the safety, tolerability, and patient management techniques for inavolisib + palbociclib + fulvestrant in 1L PIK3CAm HR+, HER2- ABC (Video 2/2)

INAVO120 safety/patient management

Gregory Vidal
ASCO Updates
Breast Cancer
+1 more
Dr. Charu Aggarwal discusses the efficacy of datopotamab deruxtecan in pretreated mNSCLC (Video 1/3)

Dr. Charu Aggarwal discusses the efficacy of datopotamab deruxtecan in pretreated mNSCLC (Video 1/3)

TROPION Lung Efficacy

Charu Aggarwal, MD
Lung Cancer
Dr. Eric Singhi reviews 5-year efficacy of cemiplimab + chemotherapy in aNSCLC (Video 1/3)

Dr. Eric Singhi reviews 5-year efficacy of cemiplimab + chemotherapy in aNSCLC (Video 1/3)

EMPOWER Squamous

Eric Singhi , MD
Lung Cancer

Why subscribe?

  • Get one-minute, non-promotional, educational videos from distinguished thought leaders
  • Tailored to topics you select
    • Breast Cancer
    • Lung Cancer
    • Gastrointestinal Cancers
    • Genitourinary Cancers
    • Gynecologic Cancers
    • Hemotologic Malignancies
    • Conference updates and more
  • No spam. No ads. No apps to download.
  • Always free and you can opt-out anytime if you feel this isn’t for you.

Fill out the form above to subscribe!

Our patented Sound Bites platform offers a convenient, unbiased way for oncologists to stay up-to-date.

Critical, on-demand information right at your fingertips when and where it is most convenient for you. Subscribe to receive 60 – 90 second video clips from thought leaders via text message.

Intended for USA healthcare providers only.

If your institution is not listed, please input the Institution / Company name in the field below.

By clicking Subscribe, I agree that I have read and understand IDEOlogy Health’s Privacy Policy and Terms and Conditions and further agree to receive information from IDEOlogy Health and its companies

ideology-health
Privacy Policy
Terms of Service
Inc. 5000

IDEOlogy Health Ranks No. 772 on the 2025 Inc. 5000 Fastest-Growing Private Companies in America

© 2025 IDEOlogy Health. All product names, logos, brands, trademarks and registered trademarks are property of their respective owners and their use(s) do not necessarily imply endorsement.